UCB SA Stock
StockStockPrice
Historical dividends and forecast
UCB SA has so far distributed $1.451 in 2024. The next dividend will be paid on 30.04.2025
CHART BY
Frequently asked questions
What is UCB SA's market capitalization?
What is UCB SA's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for UCB SA?
What are the analyst ratings and target price for UCB SA's stock?
What is UCB SA's revenue over the trailing twelve months?
What is the EBITDA for UCB SA?
What is the free cash flow of UCB SA?
What is the 5-year beta of UCB SA's stock?
How many employees does UCB SA have, and what sector and industry does it belong to?
What is the free float of UCB SA's shares?
Financials
Market Cap
$37.50B5Y beta
0.62EPS (TTM)
$1.298Free Float
119.23MP/E ratio (TTM)
148.51Revenue (TTM)
$5.76BEBITDA (TTM)
$1.27BFree Cashflow (TTM)
$327.13MPricing
Analyst Ratings
The price target is $145.75 and the stock is covered by 21 analysts.
Buy
15
Hold
6
Sell
0
Information
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
9,083
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker